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Objective: To identify disease relevant genes and pathways associated with knee Osteoarthritis (OA)
progression in human subjects using medial and lateral compartment dominant OA knee tissue.
Design: Gene expression of knee cartilage was comprehensively assessed for three regions of interest
from human medial dominant OA (n ¼ 10) and non-OA (n ¼ 6) specimens. Histology and gene expression
were compared for the regions with minimal degeneration, moderate degeneration and signiﬁcant
degeneration. Agilent whole-genome microarray was performed and data were analyzed using Agilent
GeneSpring GX11.5. Signiﬁcant differentially regulated genes were further investigated by Ingenuity
Pathway Analysis (IPA) to identify functional categories. To conﬁrm their association with disease
severity as opposed to site within the knee, 30 differentially expressed genes, identiﬁed by microarray,
were analyzed by quantitative reverse-transcription polymerase chain reaction on additional medial
(n ¼ 16) and lateral (n ¼ 10) compartment dominant knee OA samples.
Results: A total of 767 genes were differentially expressed two-fold (P  0.05) in lesion compared to
relatively intact regions. Analysis of these data by IPA predicted biological functions related to an
imbalance of anabolism and catabolism of cartilage matrix components. Up-regulated expression of IL11,
POSTN, TNFAIP6, and down-regulated expression of CHRDL2, MATN4, SPOCK3, VIT, PDE3B were signif-
icantly associated with OA progression and validated in both medial and lateral compartment dominant
OA samples.
Conclusions: Our study provides a strategy for identifying targets whose modiﬁcation may have the
potential to ameliorate pathological alternations and progression of disease in cartilage and to serve as
biomarkers for identifying individuals susceptible to progression.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.o: C.-C. Wu, Department of
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Although the progression of osteoarthritis (OA) is generally
currently unpredictable, altered biomechanical and biochemical
properties of the joint organ facilitate progression of disease1e4. It is
widely accepted that the molecular homeostasis of the joint de-
pends on both the structural integrity of articular cartilage and the
appropriate biomechanical stresses5,6. A detailed examination oftd. All rights reserved.
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cartilage during OA disease progression, is of pivotal importance for
choosing molecules that could potentially be targeted to achieve a
therapeutic beneﬁt.
Joint tissues readily available for research are generally acquired
at the time of knee joint replacement and suffer from full-thickness
or severe cartilage loss of the medial weight-bearing compartment.
This level of OA severity is often associated with an abnormal
external knee adduction moment and imbalanced load distribution
on the medial compartment of the knee7. Therefore, results of
molecular analyses of advanced medial compartment knee OA
tissue may not only represent direct effects of disease, but also site-
related effects driven by altered mechanical loading. In addition,
few studies have proﬁled human tissues for genes associated with
OA progression; this is largely due to difﬁculties obtaining joint
tissues with either early- or intermediate-stages of OA severity8,9.
Another drawback to using patient tissues for gene expression
proﬁling is large inter-patient differences due to variability in ge-
netic background, duration of disease, age and gender.
To overcome these obstacles, we have pursued a two-pronged
approach. First we have proﬁled cartilage gene expression
changes relative to a gradient of histological OA severity across the
tibial plateau in knees with medial compartment dominant dis-
ease10,11. This model system was based on evaluation of regions of
cartilage and bone across the knee joint from the uninvolved
(lateral compartment of the knee) to the involved surfaces (medial
compartment of the knee), evaluating for disease severity and site
associated gene expression changes. Because initiation of OA usu-
ally occurs in a focal subregion where the articular surface is
affectedmost by asymmetric mechanical loading12, other regions of
the articular cartilage in the joint remain macroscopically and
structurally normal or much less damaged. With disease progres-
sion, regions adjoining the damaged cartilage are affected until the
entire joint surface is involved in advanced OA13. In our previous
study we demonstrated that speciﬁc regions across the tibial
plateau yielded a gradient of disease severities; intra-individual
comparisons of these regions provided a means of overcoming
the inter-individual background variation in gene expression
studies10. This model system also provided a means to overcome
the difﬁculty of obtaining early stage disease tissue by providing
relatively normal tissue from the lateral compartment for com-
parison with the more diseased regions medially.
For the second aspect of this approach, we now proﬁle cartilage
gene expression changes relative to a gradient of histological OA
severity across the tibial plateau in knees with lateral compartment
dominant disease (LOA). Whereas medial compartment dominant
knee OA (MOA) is often associated with an abnormal external knee
adductionmoment and imbalanced load distribution on the medial
compartment of the knee, load plays less of a role in development
of OA in lateral compartment disease14,15. This may be due to the
fact that even in valgus knees, the medial compartment remains
relatively overloaded until the valgus deformity exceeds 1516. This
overcomes a third drawback described above by enabling us to
examine gene expression changes relative to worsening OA
severity in the lateral compartment that has been shown to be
relatively disassociated from loading stress.
For the current study, we hypothesized that this model system,
encompassing a full range of histological severity across the tibial
plateau, could enable us to identifygene expression changes directly
associated with knee OA progression. We hypothesized that the
pattern of gene expression for genes directly associatedwith disease
severity, as opposed to joint site or mechanical load, could be the
“mirror image”, i.e., in medial compartment dominant disease the
greatest gene expression changes associated with OA progression
should occur in themost degenerativemedial cartilagewhereas theinverse should be true for lateral compartment disease. Because
load may play less of a role in development of lateral compartment
dominant disease than medial compartment OA7,15, the identiﬁca-
tion of the severity associated genes expressed in common between
medial and lateral compartment dominant disease may more
readily identify genes related to biological factors directly associated
with OA progression that are independent of load.
Therefore, to identify gene expression patterns directly associ-
ated with effects of disease and to differentiate them from patterns
of expression that are driven by external mechanical loading and/or
site-speciﬁc alternations, we evaluated whether OA-related genes
identiﬁed in medial compartment dominant knee OA joints could
be validated in lateral compartment dominant knee OA joints. In
the present study, we performed whole genome transcriptome
analysis of three regions of interest of articular cartilage in OA and
non-OA knee joints and validated gene expression of the 30 most
differentially regulated genes in additional independent medial
(n ¼ 16) or lateral (n ¼ 10) compartment dominant knee OA joint
cartilage specimens. Ingenuity Pathway Analysis (IPA) was used to
discern the gene expression patterns most reﬂecting the different
stages of OA progression. This study identiﬁed molecular targets
that are involved in the homeostasis of cartilage integrity and
provides potential pathways for therapeutic druggable targets or
biomarkers in OA.
Materials and methods
Human knee joint tissues
A total of 42 human tibial plateaus were obtained during total
knee joint replacement surgery from patients withmedial or lateral
compartment dominant knee OA (N ¼ 26 medial OA, 10 for
microarray analysis and 16 for validation of gene expression, mean
age 68.9 ± 7.4 years, 70% female; N ¼ 10 lateral OA, mean age
73.9 ± 11.45 years, 50% female) and non-OA joints acquired at the
time of tumor surgery and above the knee amputation (N ¼ 6 non-
OA, mean age 39 ± 11.4 years, 50% female). The anatomic orienta-
tionwas indicated on the freshly isolated specimens by marker pen
to ensure consistency of sampling at prespeciﬁed regions of inter-
est. All specimens were stored immediately in liquid nitrogen. The
study was approved by the institutional review board of all the
participating hospitals and Academia Sinica, Taiwan, Written
informed consent was obtained from all of the participants.
Regions of interest, cartilage harvest and RNA isolation
The processes of cartilage harvest, sectioning, grinding, and RNA
extraction were performed as previously described in Ref. 10.
Brieﬂy, regions of interest were sectioned and powdered under
liquid nitrogen; 100 mg of articular cartilage powder was used for
RNA isolation with 5 ml of Trizol (Invitrogen, CA). The RNA con-
centration and quality (RNA integrity number, RIN and 28S/18S
ratio) were determined by a Nano-Drop (NanoDrop Technologies,
DE) and the RNA 6000 Nano Assay on an Agilent 2100 Bioanalyzer
(Agilent Technologies, CA), respectively. An adjacent section was
preserved for histological evaluation using the OARSI grading sys-
tem17 by a scorer blinded to the results of the molecular analyses.
Microarray analysis
400 ng of total RNA per sample was used for one round of cRNA
synthesis and ampliﬁcation. Cyanine 3-labeled cRNAswere puriﬁed
and hybridized to Agilent whole human genome 44k microarray
chips (Agilent Technologies, Santa Clara, CA, USA). All procedures
were carried out according to the manufacturer's instructions. The
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Spring GX software (version 11.5). All data sets were normalized by
quantile normalization and probes with low signal intensities less
than 72 were excluded. Signiﬁcant differentially expressed genes
between samples in OA patients were identiﬁed by Repeated
Measures ANOVA. Probes with a threshold of 2 fold-change and a
P-value 0.05 in gene expression were further analyzed by the hi-
erarchical clustering method, with Euclidean distance and centroid
linkage according to the manufacturer's instructions.
Pathways analysis
Signiﬁcant differentially expressed genes were uploaded into
IPA (Ingenuity Systems; www.ingenuity.com) to identify functional
annotations and predict biological interactions. The biological
interaction scores were deﬁned by the IPA statistical algorithm. The
analysis was based on the z-score and P-value (red dots), which
were calculated by the IPA regulation z-score algorithm and the
Fischer's exact test. A positive or negative z-score of more than 2 or
less than 2, and P-value less than 0.05 (log10 1.3) indicates that a
biological function is signiﬁcant and predicts that the biological
process or disease is trending towards an increase (z-score  2) or
decrease (z-score  2). In our study, some predictions with the
z-score between 1.5 and 2.0 (positive or negative) were also
considered due to their biological functions relevant to joint tissue
metabolism. P values were corrected for multiple comparisons with
the BenjaminieHochberg test.
qRT-PCR validation
To validate results from microarray analysis, 16 medial
compartment and 10 lateral compartment dominant OA joint tissue
samples were analyzed by qRT-PCR for expression of 30 genes and
GAPDH (endogenous control) (Supplementary Table I) across the
three regions of interest. The qRT-PCR was performed using the
Taqman probes (Invitrogen, CA) according to the manufacturer's
instructions and using the methods of data analysis as described in
our previous study11.
Results
Pathological evaluation of regions of interest
In specimens with medial compartment dominant OA selected
for microarray analysis, histological evaluation conﬁrmed a
gradient of disease severity across the tibial plateau (least degen-
eration laterally and most degeneration medially) [Fig. 1(A)]. By the
OARSI histological scoring system, the mean severity ranged from
4.4 ± 0.8 at the minimally damaged outer lateral tibial plateau
(oLT), to 14.8 ± 3.4 at the moderately damaged inner lateral tibial
plateau (iLT), and 19 ± 1.7 at the severely damaged inner medial
tibial plateau (iMT). In contrast, OARSI scores of specimens from
non-OA donors were 2.7 ± 2.1, 4.0 ± 0, and 4.3 ± 0.8 in oLT, iLT and
iMT regions, respectively. These data further demonstrate the his-
tological similarity of cartilage from macroscopically normal re-
gions of OA joints (oLT) and all the regions of the non-OA samples.
Thus, for the purposes of these analyses, the oLT region of the knee
with medial compartment dominant OA could be considered
normal or a very early stage of OA. The histological scores of each
sample used in the microarray analyses are shown in Fig. 1(D).
Analysis of gene expression
Whereas gene expression proﬁles in non-OA tissue could not be
segregated by region, gene expression proﬁles in OA tissue variedsigniﬁcantly by region. Signiﬁcant numbers of genes (N¼ 767) were
differentially expressed greater than two-fold in the iLT and iMT
regions compared with the oLT region: 156 in iLT only, 272 in iMT
only, and 339 genes were differentially expressed in both regions A
total of 222 genes (144 upregulated and 78 downregulated) were
expressed in a gradient pattern across the tibial plateau, i.e., they
were up or down regulated at an intermediate level in iLT regions
and further up or down regulated in iMT regions. We considered
this subset of genes to be themost likely candidates associatedwith
OA progression [Fig. 1(B) and (C), Supplementary Table II, and with
annotations by IPA in Supplementary Table III].
Unsupervised hierarchical clustering of OA and non-OA samples
was performed on the gene expression data of the differentially
regulated genes to identify mechanistic pathways of disease
development and progression. Except for two OA-iLT samples that
clustered with the OA-MT samples, OA-oLT, OA-iLT, and OA-iMT
samples grouped as distinct and separate clusters. In contrast,
non-OA samples did not cluster by sample site but were more akin
to the OA-oLT samples than to the OA-iLT and OA-iMT samples
[Fig. 1(D)].
Predicted biological functions
To more comprehensively explore the effects of gene expression
changes associated with damaged cartilage and to predict the po-
tential biological associations, differentially regulated genes with
changes greater than 1.5-fold were further examined by IPA.
Figure 2 shows predicted biological functions associated with OA
including molecular and cellular regulation and physiological sys-
tem disease. Connective tissue and vessel development were the
most strongly predicted functional pathways activated in iLT carti-
lage regions (z-score  1.5 or  1.5); these included adhesion of
connective tissue (z-score ¼ 3.63, P-value ¼ 1.41  106), ossiﬁca-
tion of bone (z-score ¼ 2.0, P-value ¼ 2.08  107), and vessel
development (ﬁve functional annotations with z-scores over 2.0
and one below 2.0). Biological functions predicted to be inhibited
in cartilage (z-score  1.5) were related to cell signaling, cellular
metabolism, movement, and quantity and growth; these included
binding of endothelial cells (z-score¼2.59, P-value¼ 3.18 107),
metabolism of acylglycerol (z-score¼2.27, P-value¼ 8.96106),
migration of cells (z-score¼2.4, P-value¼ 8.88 1025), quantity
of leukocytes (z-score ¼ 2.1, P-value ¼ 1.08  109), and prolif-
eration of chondrocytes (z-score¼1.88, P-value¼ 1.10 105). All
of these predicted biological functions point to an imbalance of
anabolism and catabolism of cartilage matrix components.
In iMT regions, biological functions predicted to be activated in
damaged cartilage (z-score 1.5) were related to tissuemorphology,
cellular growth and tissue development; these includedmorphology
of cells (z-score ¼ 2.51, P-value ¼ 4.36  1010), formation of con-
nective tissue cells (z-score ¼ 2.31, P-value ¼ 2.14  106) and adhe-
sion of connective tissue cells (z-score¼ 3.88, P-value¼ 2.35107).
These predictions support our histological results characterizing the
structural degeneration of OA cartilage. In contrast, biological func-
tions predicted to be inhibited in damaged cartilage (z-score 1.5)
were related to cellular movement, a connective tissue disorder,
immunological disease, metabolism, cell cycle and cell death, prolif-
eration of chondrocytes (z-score¼1.82, P-value¼ 1.67 107), and
development of body axis (z-score ¼ 2.32, P-value¼ 3.92 1015).
These countermeasuresmight indicate that cells indamagedcartilage
try to protect against the invasion of other cells and reduce immune
responses, but the growth rate of major cells (chondrocytes) was
inhibited as well.
In addition to surveying the most differentially regulated genes,
we also examined our microarray data for the set of protease genes
(581) listed in theDegradomedatabase (online at http://degradome.
Fig. 1. Microarray gene expression analysis of OA and non-OA articular cartilage. (A) Representative histological images of cartilage for RNA isolation from the oLT, iLT and iMT from
specimens with medial compartment dominant OA. (B) Cumulative frequency distribution of the number of differentially expressed genes with a minimum of two-fold, three-fold,
four-fold, six-fold, and eight-fold changes from iLT and iMT samples (gray and blue lines). Fold change (x-axis) is plotted against the number of differentially expressed genes (bars)
and also against the cumulative frequency (lines). (C) Venn diagram indicating the overlap of differentially expressed genes from iLT and iMT samples. (D) Heat map and unsu-
pervised hierarchical clustering of OA and non-OA samples were performed for genes whose differential expression exceeded two-fold (767 genes from 894 probes). Distances
between samples were detected with a Euclidean algorithm and clustered with an average linkage method. The OA-oLT (pink), OA-iLT (gray) and OA-iMT (blue) samples clustered
separately from one another and non-OA samples, except for two iMT samples. Non-OA-oLT (green), non-OA-iLT (brown) and non-OA-MT samples manifested a mixed pattern. The
cartilage integrity of each sample was determined by the OARSI histological grading system and these scores were merged with the heatmap (gray dots and line). Samples with
scores under six clustered into a subgroup (e.g., OA-oLT and all non-OA samples) separate from OA-iLT and OA-iMT samples.
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protease or protease inhibitor genes that were differentially regu-
latedmore than two-fold in cartilage at intermediate and late stages
of OA. Pathwayanalysis of the 30most differentially regulated genes
(15 up- and 15 down-regulated) and the 46 differentially regulated
protease genes identiﬁed a novel signaling network in OA entitled“post-translational modiﬁcation, protein degradation, and protein
synthesis”. Interestingly, except for VIT, all of the most up- and
down-regulated genes could be directly or indirectly linked to this
network (Supplementary Fig. 1). This pathway provides a compre-
hensive network encompassing regulation of protein quality and
quantity in either cells or cartilage in OA progression.
Fig. 2. Representative molecular and cellular functions identiﬁed in iLT and MT regions compared with oLT regions. To predict potential biological associations of the differentially
expressed genes, microarray data from iLT (A) and iMT (B) regions of medial compartment dominant OA were further examined by IPA (http://www.ingenuity.com). Predicted
biological functions included molecular and cellular regulation and physiological system disease. The analysis was based on the z-score and P-value (red dots), which were
calculated by the IPA regulation z-score algorithm and the Fischer's exact test. A positive or negative z-score with more than 2 or less than 2 fold difference, respectively and P-value
less than 0.05 (log10  1.3) indicate that a biological process or disease increases (z-score  2, represented by orange dotted lines) or decreases (z-score  2, represented by blue
dotted lines) signiﬁcantly.
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the early events in OA, those differentially expressed in regions of
intermediate OA severity; IPA analysis identiﬁed changes of extra-
cellular matrix properties and microenvironment, which may
induce bone remodeling, bone cell differentiation and neo-
vascularization reaching to the deep layer of cartilage
(Supplementary Fig. 2). In addition to the predicted biological
functions of differentially regulated genes, several predicted ca-
nonical pathways also showed consistent changes in expression
with OA progression across early, intermediate and late stages of
cartilage degradation; these pathways included a major inﬂam-
matory response pathway (IL-6 and acute phase response
signaling) in intermediate stage cartilage, a bone development
pathway (Wnt/b-catenin and BMP signaling pathways) in late stage
cartilage damage, and changes in the quality of cartilage and bone
(role of osteoblasts, osteoclasts, and chondrocytes) in both inter-
mediate and late stage cartilage damage (Supplementary Table V).
All of these data reveal that these differentially regulated genes,
identiﬁed through our model system, are plausibly associated with
the pathogenesis of OA and disease progression.qRT-PCR validation of differentially regulated genes in medial (MOA)
and lateral compartment OA (LOA)
Based on the results of the histological and biological function
evaluation of the initial samples with medial compartment domi-
nant OA, we deﬁned oLT, iLT and iMT regions as early (E), inter-
mediate (IM), and late (L) stages of OA, respectively [Fig. 3 (A) and
(C)]. This disease severity pattern was mirrored for lateral
compartment dominant disease [Fig. 3 (B) and (D)]. We hypothe-
sized that gene expression effects speciﬁc to disease, as opposed to
a site within the joint, would track with the histological severity of
disease; by this reasoning, we would expect that disease speciﬁcgene regulationwould be maximal in the compartment of maximal
histological damage, independent of site (medial or lateral
compartment). To test this hypothesis, human osteoarthritic tibial
plateaus with either medial (MOA n ¼ 16) or lateral (LOA n ¼ 10)
compartment dominant OA were obtained during total knee joint
replacement surgery from knee OA patients. In the MOA samples,
the mean histological severity ranged from 4.6 ± 1.2 at the mini-
mally damaged oLT region, to 14.5 ± 3.5 at themoderately damaged
iLT region, and 19.3 ± 1.8 at the severely damaged iMT region. In
LOA samples, the mean severity ranged from 5.8 ± 2.4 at the
minimally damaged outer medial tibial plateau (oMT), to 11.2 ± 2.7
at the moderately damaged iMT, and 18.4 ± 3.8 at the severely
damaged iLT. Except for BHLHE22 (due to failure of the qPCR probe
design), all the genes with the greatest up- and down-regulated
expression in microarray could be validated in independent MOA
samples by qRT-PCR (Table I). Analysis of LOA samples demon-
strated that the expression pattern of three up-regulated genes and
ﬁve down-regulated genes reproduced results with MOA samples
(i.e., in a “mirror image pattern”), and their expression occurred in a
gradient pattern corresponding to the gradient of disease severity;
these included up-regulated IL11, POSTN, TNFAIP6, and down-
regulated CHRDL2, MATN4, SPOCK3, VIT, PDE3B. Additionally, up-
regulated CDH10 and GALNTL1 could be validated in moderately
damaged cartilage [Fig. 3(E)], whereas up-regulated TNFSF11,
LOXL2, and down-regulated LMO3, DACT1, MMP3, RSPO3, ADCY1,
C4BPA and NRXN2 could be validated in severely damaged cartilage
[Fig. 3(F)].Upstream regulators of differentially regulated genes
Upstream regulator analysis may identify proximal transcrip-
tional control mechanisms responsible for OA-related gene regu-
lation (differentially regulated genes) and forecast upstream targets
Fig. 3. Validation of top OA genes in medial and lateral compartment dominant knee OA. A total of three regions of interest were chosen for RNA isolation and histological
analysisdindicated by the black-boxed areas. The macroscopic appearance and histological scores of tibial plateau regions of interest are shown for human medial compartment
dominant knee OA (MOA, N ¼ 16, panels A and C) and lateral compartment dominant knee OA (LOA, N ¼ 10, panels B and D). The cartilage from the oLT, iLT and iMT fromMOA knees
were designated early (E), intermediate (IM) and late (L) stages of OA, respectively based on their histological scores. The cartilage from the outer medial tibial plateau (oMT), iMT,
and iLT from LOA knees were designated E, IM and L, respectively. The histological severity scores across MOA and LOA regions were signiﬁcantly different. (non-parametric
repeated measures test, P < 0.001 for MOA, P < 0.001 for LOA). (EeF) 10 and 17 genes were validated in IM and L stage of OA samples, respectively in both MOA and LOA (n ¼ 16
MOA, n ¼ 10 LOA). The eight genes shown left of the dashed line were validated in both IM and L stages of OA in both MOA and LOA; error bars represent 95% conﬁdence intervals.
C.-H. Chou et al. / Osteoarthritis and Cartilage 23 (2015) 571e580576
Table I
Top up- and down-regulated genes comparing outer lateral tibial cartilage (intact cartilage) to inner lateral or medial tibial cartilage (damaged cartilage)
Accession no. Gene symbol Gene name P Medial compartment OA Lateral compartment
OA
iLT (OA) iMT (OA) iLT (N) iMT (N) iLT (OA) iMT (OA) iMT (OA) iLT (OA)
Microarray (FC) Microarray (FC) qRT-PCR (FC), n ¼ 16 qRT-PCR (FC), n ¼ 10
Genes with increased expression in inner lateral or medial tibial cartilage
NM_000641 IL11 interleukin 11 4.69E-06 5.63 180.87 1.28 1.99 63.93x 450.07x 3.14* 11.07¶
NM_139072 DNER delta/notch-like EGF repeat containing 1.02E-07 42.53 67.22 10.82 4.60 19.93x 23.71x 1.61 1.15
NM_003108 SOX11 SRY (sex determining region Y)-box 11 2.79E-05 14.54 29.84 9.52 2.20 7.45x 5.57* 2.80* 1.28
NM_006475 POSTN periostin 7.52E-05 5.31 19.70 2.90 1.09 2.31 4.30x 3.42x 10.83¶
NM_004878 PTGES prostaglandin E synthase 4.44E-05 5.51 12.73 1.30 1.87 6.00x 8.02x 1.97¶ 1.87*
NM_000066 C8B complement component 8 1.65E-04 7.55 10.81 1.23 1.30 3.06¶ 2.94¶ 1.77 6.09x
NM_024812 BAALC brain and acute leukemia, cytoplasmic 1.16E-07 3.80 10.75 1.86 1.51 7.29x 10.87x 1.76 1.30
NM_006727 CDH10 cadherin 10, type 2 4.48E-05 7.89 10.60 1.24 1.46 15.84x 18.91x 2.39* 1.03
NM_001001557 GDF6 Homo sapiens growth differentiation factor 6 2.61E-03 5.50 9.87 1.49 1.29 1.88 4.61* 1.43 1.07
NM_003701 TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 1.78E-05 4.07 9.50 1.39 1.17 3.99 7.69¶ 1.40 2.31¶
NM_020692 GALNTL1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase-like 1
1.63E-05 5.57 9.17 2.36 1.18 27.11x 23.55x 2.15* 1.08
NM_001495 GFRA2 GDNF family receptor alpha 2 8.70E-06 4.07 8.99 1.45 1.53 7.50x 7.84x 1.84 1.12
NM_007329 DMBT1 deleted in malignant brain tumors 1 2.06E-05 3.95 8.39 1.10 1.72 4.77x 4.40¶ 1.50 2.09
NM_002318 LOXL2 lysyl oxidase-like 2 9.73E-05 4.73 7.73 1.76 1.64 3.32x 4.21x 1.58 2.39*
NM_007115 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 3.11E-03 2.86 7.14 1.00 1.08 5.01* 9.18x 2.85x 4.42x
Genes with decreased expression in inner lateral or medial tibial cartilage
NM_015424 CHRDL2 chordin-like 2 5.79E-05 4.39 24.62 3.52 1.62 23.23x 112.37x 4.40¶ 383.46x
NM_003833 MATN4 matrilin 4 1.23E-05 26.28 16.73 2.50 1.74 31.68x 36.39x 2.57* 22.55x
NM_001204352 SPOCK3 sparc/osteonectin, cwcv and kazal-like domains
proteoglycan (testican) 3
1.18E-03 3.83 7.45 14.34 5.88 59.51x 78.33x 3.94 29.07x
NM_053276 VIT vitrin 1.10E-05 4.50 7.34 5.15 3.23 23.24x 51.19x 3.13¶ 7.04*
NM_152414 BHLHE22 basic helix-loop-helix family, member e22 6.55E-03 4.01 7.33 1.48 4.08 NA NA NA NA
NM_000922 PDE3B phosphodiesterase 3B, cGMP-inhibited 6.49E-07 5.03 7.32 3.35 2.38 8.85x 17.15x 3.02¶ 9.98x
NM_018640 LMO3 LIM domain only 3(rhombotin-like 2) 1.69E-04 3.88 7.19 3.41 2.41 11.25x 15.30x 2.52 7.33x
NM_016651 DACT1 antagonist of beta-catenin, homolog 1 3.19E-06 5.20 5.81 1.79 1.60 11.27x 16.80x 1.23 9.39x
NM_002422 MMP3 matrix metallopeptidase 3 3.48E-04 3.46 5.42 4.41 2.46 9.41¶ 34.96x 1.33 11.35x
NM_032784 RSPO3 R-spondin 3 1.11E-05 3.28 5.24 1.84 1.62 4.16 8.71x 1.75 16.73¶
NM_021116 ADCY1 adenylate cyclase 1 2.06E-05 3.66 5.17 1.37 2.26 6.25x 11.16x 1.48 7.09¶
NM_153692 HTRA4 HtrA serine peptidase 4 1.90E-02 4.20 4.77 1.01 1.45 1.97 3.66 1.01 1.47
NM_001205315 STEAP4 STEAP family member 4 7.79E-05 4.20 4.53 1.17 2.01 7.21x 11.09x 1.55 3.00
NM_000715 C4BPA complement component 4 binding protein, alpha 3.32E-05 4.75 4.46 3.25 2.47 16.04x 23.12¶ 1.46 9.74¶
NM_138732 NRXN2 neurexin 2 3.16E-06 4.27 3.57 1.51 1.17 7.47¶ 10.09x 2.86 7.56*
iLT ¼ inner lateral tibail plateau, iLT ¼ inner lateral tibial plateau, iMT ¼ inner medial tibial plateau, N ¼ non-OA sampels, FC ¼ Fold change, NA ¼ not analyzed, x: P < 0.001, ¶: P < 0.01, *: P < 0.05.
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identify potential therapeutic and biomarker targets. A total of 105
signiﬁcant upstream regulators were predicted by IPA based on
signiﬁcant z-scores (Supplementary Table VI). Table II shows the
top upstream regulators, currently available drugs targeting these
upstream regulators and potential expressing cells identiﬁed by IPA
analysis and their predicted activation state. These analyses
revealed that TNF, TGFB1, PPARG, ERBB2 and SMAD4 would be
potential upstream regulators at intermediate and late stages of OA
severity. These regulatory molecules might be released by chon-
drocytes in cartilage, immune cells (e.g., macrophages) in synovial
ﬂuid, synovium, or bone cells (e.g., osteoblasts) in underlying
subchondral bone.
Discussion
For this study we evaluated histological and transcriptomic
changes of three regions of interest across the tibial plateau
encompassing a wide range of disease severities. All the most
strongly differentially expressed genes except one, identiﬁed byTable II
Summary of representative predicted upstream regulator identiﬁed in iLT and MT region
Regulator Type iLT iMT
z-score P-value z-score
CEBPA* TR 2.42 4.4E-08
CEBPB TR 2.26 5.9E-08
COMMD1 T 2.24 8.3E-05
IL13 CK 2.17 1.5E-04
tretinoin CH 2.03 4.4E-09
NCOA1 TR 2.01 1.1E-06
HOXD3 TR 2.00 7.2E-04
TGFB1 GF 3.08 1.1E-14 5.68
TNF CK 2.57 5.2E-19 3.80
ERBB2 K 2.19 1.7E-10 2.57
PIN1 E 2.00 1.2E-02 2.24
SMAD4 TR 2.08 4.5E-04 2.79
MTTP T 2.00 1.6E-03 2.00
ENPP2 E 2.00 8.9E-05 2.00
TGM2 E 2.53 3.8E-02 2.78
NCOA3 TE 2.42 4.6E-04 2.21
PPARG* LNR 2.41 1.0E-11 2.16
CXCL12* CK 2.38 4.2E-03 2.03
MEDAG* other 2.24 3.8E-07 2.00
PARP2 E 2.22 8.4E-07 2.00
IDH1 E 2.00 5.0E-05 2.00
IGF2 GF 3.23
HIF1A TR 2.83
CTNNB1 TR 2.47
IGF1* GF 2.75
GDF2 GF 2.71
F2 P 2.51
EGFR K 2.48
prostaglandin E2 CH 2.47
TGFB2 GF 2.37
WNT3A CK 2.36
progesterone CH 2.31
BMP2* GF 2.31
FGF2 GF 2.29
BMP6* GF 2.21
NCOR2 TR 2.18
MAPK3 K 2.16
PDGF BB CO 2.10
EGF GF 2.07
let-7a-5p mR 3.25
NOG* GF 2.43
miR-16-5p mR 2.43
APC E 2.21
CR1L other 2.16
TR ¼ transcription regulator, T ¼ transporter, CK ¼ cytokine, CH ¼ chemical, GF ¼ gr
P ¼ peptidase, CO ¼ complex, mR ¼mature microRNA, P/S ¼ Plasma/Serum, S/SF ¼ Synov
* ¼ FC  2 or  2.microarray in medial compartment dominant disease, could be
validated by qRT-PCR in independent medial compartment domi-
nant knee OA specimens. Eight of these most differentially
expressed genes in medial compartment dominant knee OA were
mirrored in lateral compartment dominant knee OA; namely, in-
dependent of site, each of these genes was expressed in a gradient
pattern across the tibial plateau, either positively or negatively with
respect to histological disease severity. The genes expressed in the
lateral compartment dominant disease mirrored the pattern of
gene expression in the medial compartment dominant disease
suggesting that these genes are disease severity related rather than
site dependent. Although some of these genes, according to the
available literature, have not previously been associated with OA
progression in humans, their involvement is plausible given their
known functions. For instance, although its role in OA progression
is still unclear, IL-11 is a member of the IL-6-type cytokine family
whose up-regulation is associated with anti-inﬂammation in hu-
man cartilage18. The role of POSTN in OA progression is also un-
known; POSTN is a matricellular glutamate-containing protein that
plays multiple roles in bone metabolism and is an importants compared with oLT regions
Drug(s) Expressing cells/tissues
P-value P/S S/SF OB C M
x x
x x x
x
x x x
x
5.2E-26 x x x
4.1E-28 x x x x x
1.3E-14 x x
4.4E-03 x
7.9E-08 x
2.7E-05 x
1.9E-04 x x
2.2E-05 x
2.7E-04 x
1.1E-15 x x x x
5.7E-03 x x x x x
4.3E-05
7.5E-05 x
1.3E-03 x x x
2.6E-10 x x
1.7E-07 x x
6.7E-14 x
2.8E-11 x x x x
8.0E-06
6.1E-08 x x
2.7E-12 x x x x
5.6E-10
4.9E-05 x x
5.2E-11
1.9E-19
3.0E-07 x x
6.2E-12 x x x x
3.8E-05
4.3E-09 x
7.9E-07 x
3.0E-08
1.0E-08 x
2.7E-03
3.6E-06 x
2.3E-03
6.8E-07 x
4.3E-07 x
owth factor, K ¼ kinase, E ¼ enzyme, LNR ¼ ligand-dependent nuclear receptor,
ium/Synovial Fluid, OB ¼ Osteoblasts, C ¼ Cartilage/Chondrocyte, M ¼Macrophage,
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important initiator of subchondral bone turnover. TNFAIP6 (tumor
necrosis factor, alpha-induced protein 6) is a third example of a
genewhose role in OA progression is unclear. TNFAIP6 is a secretory
protein that contains a hyaluronan-binding domain; increased
levels of this protein are found in the synovial ﬂuid of patients with
OA and OA progression20. Therefore, the present study provides
strong proof of the concept that this model system recapitulates
states of OA progression and provides disease-relevant molecular
signatures.
To date, gene expression studies have been conducted in several
animal models to identify genes associated with progressive
degeneration of articular cartilage21e26. Surgical destabilization of
the medial meniscus (DMM) was performed in mice lacking
ADAMTS-5 activity to identify OA initiation and progression can-
didates involved in cartilage destruction independent of ADAMTS-
527. Identiﬁed genes included Il-11,Mmp3, Ptgs2, Crlf1, Inhba, Capn2,
Press46, Klk8 and Phdla2. With the exception of Press46 and Klk8, all
of these genes are among the differentially expressed genes in our
study. Moreover, both IL-11 and MMP3 are among the top-
dysregulated genes that could be validated in both LOA and MOA
joint cartilage. Interestingly, some of the genes signiﬁcantly asso-
ciated with disease progression in the current study (such as
ADAMTS1, ASPN and TNFSF11) were previously identiﬁed to be
among our 19 human genes associated with the interaction of
articular cartilage and subchondral bone10.
Of the eight genes that could be validated as disease associated
in bothMOA and LOA samples, seven genes have been implicated in
the organization of cartilage extracellular matrix, cartilage devel-
opment or OA pathogenesis18e20,28e31. The single exception, the
PDE3B gene, has not been implicated previously in OA. Neverthe-
less, its involvement in OA is plausible based on previous data
showing that activation of PDE3B likely serves as a regulatory feed-
back mechanism of cAMP and calcium related responses and plays
an important role in regulating energy homeostasis32.
Although several candidate biomarkers have been investigated
and some potential structure-modifying OA drugs (SMOADs) and
disease-modifying OA drugs (DMOADs) have shown efﬁcacy in OA
models, currently, the practical use of these biomarkers is still
limited and no DMOADs have been proved to slow or stop disease
progression or repair damaged cartilage33,34. A discovery of up-
stream regulators of differentially regulated genes could be away of
aiding development of pharmaceutical interventions. Based on IPA
analysis, 105 molecules were predicted to be upstream regulators
mediating the observed phenotypic or functional outcomes of
cartilage damage. The molecules regulating gene expression
changes in chondrocytes from intermediate stage cartilage (N¼ 28)
may potentially be associated with driving a catabolic and
increased joint tissue turnover phenotype in chondrocytes. These
same molecules represent potential candidate biomarkers and
candidates whose inhibition might engender new DMOAD devel-
opment. Drugs designed to target upstream regulators identiﬁed
from late stage cartilage could be potential DMOADs to suppress
the dominant catabolic phenotype and disease progression before
irreversible joint failure. Moreover, the upstream regulators
involving both intermediate and late stage cartilage may affect the
homeostasis of whole joint tissue and represent additional inter-
esting targets. For example, TGFb (z-scores 3.08 in IM, 5.68 in L) and
SMAD4 (z-scores 2.08 in IM and 2.79 in L) were predicted as sig-
niﬁcant upstream regulators in our study. TGFb could be released
from underlying subchondral bone cells in response to OA pro-
gression in early stages; this is plausible given that TGFb signaling is
associated with initiation of pathological OA changes including
turnover of subchondral bone, a high level of angiogenesis and
cartilage loss35. Activated TGFb could result in phosphorylation ofSMAD4 and its translocation to the nucleus to modify gene
expression to change the balance between cartilage matrix catab-
olism and anabolism in chondrocytes36. Therefore, drugs or bio-
markers designed to target TGFb/SMAD4 signaling cascades could
be potential chondroprotective therapeutics.
Our study provides a comprehensive gene expression proﬁle
related to the pathogenesis of OA and OA disease progression.
Overall, our study provides a strategy, using a novel model system,
for identifying targets whose modiﬁcation may have the potential
to ameliorate pathological alterations and progression of disease in
cartilage and to serve as biomarkers for identifying individuals
susceptible to progression.
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